ACC 2017: A Therapeutic Update to Reduce Risk and Optimize Outcomes for Patients with Reduced or Preserved Ejection Fraction Heart Failure
This Official Elsevier Clinical Perspectives and Analysis will cover data presented at the American College of Cardiology 66th Annual Scientific Sessions and Expo held in Washington, DC. The four expert faculty will discuss the most up to date statistics and therapeutic advances for patients with preserved ejection fraction heart failure. The faculty will debate measures of prognosis and biomarkers to enhance treatment plans. Current clinical trial data will be examined in cross reference with new and emerging combination therapies to better serve patients. Upon completion of this activity physicians will gain a better understanding of treatment options to provide better outcomes for patients with ejection fraction heart failure.
This activity has been designed to meet the educational needs of cardiologists, primary care physicians, and other healthcare professionals who care for patients with heart failure.
Upon completion of this activity, participants will be better able to do the following:
- Discuss biomarkers, prognostic indicators and classification criteria for the treatment of reduced or preserved ejection fraction heart failure.
- Analyze clinical trial data of current and emerging combination therapies for the treatment of heart failure, including its role in reducing risk of hospitalizations, presented at ACC 2017.
- Develop optimal therapeutic strategies to manage patient-specific disease to improve outcomes for patients with preserved ejection fraction heart failure.
James Louis Januzzi, MD
Javed Butler, MD, MPH
Ileana L. Pina, MD, MPH
Scott David Solomon, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|James Louis Januzzi, MD|
Consultant/Advisor: Amgen Inc; Boehringer Ingelheim GmbH; Janssen Global Services, LLC; Novartis Pharmaceuticals Corporation
Grant/Research Support: Amgen Inc; Boehringer Ingelheim GmbH; Janssen Global Services, LLC; Novartis Pharmaceuticals Corporation
Javed Butler, MD
Consultant/Advisor: Amgen Inc; AstraZeneca; Bayer AG; Boehringer Ingelheim GmbH; CardioCell, LLC; Janssen Global Services, LLC; Merck & Co., Inc; Novartis Pharmaceuticals Corporation; Relypsa Inc; ZS Pharma
Ileana L. Piña, MD, MPH
Nothing to Disclose
|Scott David Solomon, MD|
Consultant/Advisor: Amgen Inc; Novartis Pharmaceuticals Corporation
Grant/Research Support: Amgen Inc; Novartis Pharmaceuticals Corporation
Non-faculty: Timothy Hayes, MD, PhD; Emma Gilmartin; Megan Gentile; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.
This CME activity has been supported by an independent educational grant from Novartis Pharmaceuticals Corporation.
Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.
CME Credit (Physicians)
The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, AcademicCME, and Novartis Pharmaceuticals Corporation. do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician